Dhyani Paramita Wahyudi

Dhyani Paramita Wahyudi

Auto-generated profile, based on publicly available information

Dhyani Paramita Wahyudi

Faculty of Medicine Jakarta Special Capital Region of Jakarta Universitas Pembangunan Nasional Veteran Jakarta

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Narra J
Verified
Journal Article
Open access
PDF file
SYSatya W. Yenny
Satya W. Yenny
JJJamsari Jamsari
Jamsari Jamsari
AHAuliya A. Hazmi
Auliya A. Hazmi
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
WHWafiq Hanifah
Wafiq Hanifah
CTChristopher D. Tristan
Christopher D. Tristan
Skin aging is one of the degenerative processes influenced by tyrosinase, elastase, collagenase, hyaluronidase, and matrix metalloproteinase-9 (MMP9) activity. One promising avenue for discovering antiaging therapeutics is the peptides from the Arbacia lixula spine. The aim of this study was to explore the potential of peptides from A. lixula spine as a multitarget inhibitor for recombinant antiaging therapies through in silico approaches. The crystal structure of peptides previously identified in A. lixula spine was visualized using the UCSF Chimera. The protein data bank (PDB) database was used to obtain the crystal structures of protein targets. The webservers Innovagen, AllerTop, and ToxinPred were utilized to predict the peptide's water solubility, toxicity, and allergenicity. MOE application was used to prepare all ligands and proteins, molecular docking, and visualization. Molecular dynamics simulations were carried out on the protein-ligand complexes on Yasara Dynamics application. The Benchling website was used to perform virtual electrophoresis and reconstruct the recombinant plasmid (Psb1c3). Based on the molecular docking results, peptide REGSPDLLE has the potential as a multitarget inhibitor of tyrosinase (-9.07 kcal/mol), hyaluronidase (-10.57 kcal/mol), elastase (-9.32 kcal/mol), collagenase (-10.57 kcal/mol), and MMP9 (-10.43 kcal/mol). Peptide REGSPDLLE was selected due to its strong binding affinity on the active site of each target protein and exhibits non-toxic, non-allergenic, and good water-soluble as indicated by Support Vector Machine score <0. Molecular dynamics simulations confirmed stable interactions with receptor proteins. Peptide REGSPDLLE was successfully inserted into the recombinant pSB1C3 plasmid, confirmed by virtual electrophoresis with bands at ~2000 bp and ~150 bp. Further in vitro and in vivo studies are necessary to verify the anti-aging efficacy of peptide REGSPDLLE.

1 January 2025 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
RRRauza Sukma Rita
Rauza Sukma Rita
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
SKSalsabila P. Khairani
Salsabila P. Khairani
RPRizky E. Putera
Rizky E. Putera
VAVella Amalia
Vella Amalia
AKAndi A. D. Kahar
Andi A. D. Kahar
Context: Colorectal cancer (CRC) remains a significant global health challenge despite advances in treatment modalities. The coelomic fluid of Lytechinus variegatus emerges as a rich source of bioactive peptides with the potential as a new therapeutic anticancer agent. Aims: To analyze the toxicity, allergenicity, and potential of L. variegatus coelomic fluid peptides as multitarget inhibitor agents of CRC cancer cells through an in silico study. Methods: Ten peptides from L. variegatus coelomic fluid were processed using UCSF Chimera software to model the three-dimensional structure. ToxinPred and AllerTop web servers were used to analyze the toxicity and allergenicity of peptides, respectively. The 3D structures of EGFR, AKT1, GSK3B, VEGFR2, and JAK3 were retrieved from the PDBJ database. MOE Software was used to perform molecular docking. Results: Peptide 4 binds to the ATP binding pocket of GSK3B protein with the strongest binding affinity value (-8,68 kcal/mol). The docking results between EGFR and peptides showed that peptide 10 binds to the ATP binding pocket with the lowest binding affinity (-9.52 kcal/mol). Peptide 2 binds to the ATP binding pocket of AKT1 with the lowest binding affinity value (-9.16 kcal/mol). Peptide 3 has the lowest binding affinity value of the JAK3 ATP binding pocket (-8,67 kcal/mol). Peptide 7 binds to the ATP binding pocket of VEGFR2 with the strongest binding affinity (-9,67 kcal/mol). Conclusions: The L. variegatus peptides have the potential as multitarget anti-CRC agents by inhibiting the activity of GSK3B, EGFR, AKT1, JAK3, and VEGFR2 proteins through the ATP competitive inhibitor action based on in silico study.

21 April 2025 in Narra J
Verified
Journal Article
Open access
PDF file
DADessy Arisanty
Dessy Arisanty
SKSalsabila P. Khairani
Salsabila P. Khairani
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
DWDhyani P. Wahyudi
Dhyani P. Wahyudi
IKIsna C. Kamila
Isna C. Kamila
AAAl H. Ariouso
Al H. Ariouso
Atherosclerosis is a leading cardiovascular disease characterized by the buildup of plaques within arterial walls. The aim of this study was to investigate the potential of peptides derived from Lytechinus variegatus spines as novel therapeutic agents for atherosclerosis using an in silico approach. Key proteins involved in atherosclerosis were selected as target proteins: vascular endothelial growth factor receptor (VEGFR), protein kinase B (AKT1), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 8 (MAPK8), and endothelin-1 (ET-1). Comprehensive analysis involving ligand and protein preparation, toxicity, and allergenicity assessments, absorption, distribution, metabolism and excretion (ADME) predictions, and molecular docking were conducted to evaluate the safety, pharmacokinetic properties, binding affinity (kcal/mol), root mean square deviation (RMSD) (Å), as well as a 2D and 3D visualization. Toxicity predictions revealed that peptide 9 was non-toxic and non-allergenic, with a lethal dose 50 (LD50) of 3,000 mg/kg, indicating its safety. Peptide 9 demonstrated the most promising results, effectively inhibiting VEGFR2 (-10,90 kcal/mol), AKT1 (-10,56 kcal/mol), EGFR (-9,82 kcal/mol), MAPK8 (-9,64 kcal/mol), and ET-1 (-11,41 kcal/mol) with strong binding affinities and specificity. These interactions suggested that peptide 9 from Lytechinus variegatus spines may serve as a competitive multitarget inhibitor, offering potential multitarget therapeutic activity against atherosclerosis. Peptide 9 also had high water solubility and did not affect the concentration or excretion of other drugs or compounds, minimizing the risk of drug-drug interactions.

16 April 2026 in F1000Research
Verified
Journal Article
Open access
PDF file
APANDI DARMA PUTRA
ANDI DARMA PUTRA
ARAldi Tamara Rahman
Aldi Tamara Rahman
LSLasmini Syariatin
Lasmini Syariatin
NDNaufal Syafiq Darmawan
Naufal Syafiq Darmawan
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
CTChristopher Daniel Tristan
Christopher Daniel Tristan
Background Endometrial cancer (EC) represents one of the most common gynecologic malignancies in the world. Despite advancements in imaging and histopathology, the early detection of EC remains suboptimal. MicroRNAs (miRNAs), known for their stability in biofluids and regulatory role in tumor biology, have emerged as promising non-invasive biomarkers. This meta-analysis evaluates the diagnostic performance of miRNAs in EC. Methods A systematic review and meta-analysis were conducted following PRISMA guidelines. Searches were performed in major databases up to August 2025. Studies reporting the sensitivity and specificity of miRNA-based diagnostics for EC were included. Pooled diagnostic performance, such as sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio (DOR), and area under the ROC curve (AUC), was calculated using a bivariate random-effects model. Subgroup analyses and sensitivity tests were conducted to explore heterogeneity and assess robustness. Results Fifty-two studies from 12 articles involving 1,098 EC patients and 957 controls were analyzed. The pooled sensitivity and specificity were 0.86 (95% CI: 0.82–0.89) and 0.81 (95% CI: 0.75–0.85), respectively. The DOR was 20.9, and the AUC was 0.91, indicating high overall diagnostic accuracy. Subgroup analyses revealed superior performance for miRNA panels and serum-based assays. Sensitivity analyses confirmed the model’s stability. No significant publication bias was detected. Conclusions Circulating miRNAs demonstrate high diagnostic accuracy for EC and may serve as effective non-invasive tools for early detection. Further prospective studies with standardized protocols are essential for clinical translation.

31 October 2026 in F1000Research
Verified
Journal Article
Open access
PDF file
APANDI DARMA PUTRA
ANDI DARMA PUTRA
ARAldi Tamara Rahman
Aldi Tamara Rahman
LSLasmini Syariatin
Lasmini Syariatin
NDNaufal Syafiq Darmawan
Naufal Syafiq Darmawan
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
CTChristopher Daniel Tristan
Christopher Daniel Tristan
Background Endometrial cancer (EC) is a common gynecologic malignancy with a growing need for accurate, minimally invasive diagnostic biomarkers. MicroRNAs (miRNAs) are stable across multiple biological specimens and have emerged as promising diagnostic candidates. This meta-analysis evaluated the diagnostic performance of single-miRNA biomarkers and multi-miRNA panels for EC. Methods A systematic review and diagnostic test accuracy meta-analysis was conducted according to PRISMA 2020. PubMed/MEDLINE, Embase, Web of Science, and ScienceDirect were searched through August 2025. Only one diagnostic estimate per independent participant cohort was included within each co-primary analysis. Single-miRNA biomarkers and multi-miRNA panels were analyzed separately using bivariate random-effects models. Pooled sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio (DOR), and SROC AUC were estimated. Results Eleven articles were included. Eight independent estimates contributed to the single-miRNA analysis and five to the multi-miRNA panel analysis. Single miRNAs yielded a pooled sensitivity of 0.90 (95% CI 0.82–0.95), specificity of 0.87 (0.75–0.94), DOR of 59.96 (18.59–193.37), and AUC of 0.95 (0.92–0.96). Multi-miRNA panels showed a sensitivity of 0.92 (0.87–0.95), specificity of 0.95 (0.88–0.98), DOR of 212.96 (67.84–668.52), and AUC of 0.95 (0.93–0.97). Sensitivity analyses supported the overall robustness of the findings. Conclusions MiRNA-based biomarkers show promising diagnostic discrimination for EC, but current evidence remains insufficient for routine clinical implementation. Prospective multicenter validation with standardized assays and prespecified thresholds is required.

26 August 2026 in Future Cardiology
Verified
Journal Article
Closed access
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
CTChristopher Daniel Tristan
Christopher Daniel Tristan
IHIndah Kurnia Hutabarat
Indah Kurnia Hutabarat
VWVina Sari Nugrahaning Widi
Vina Sari Nugrahaning Widi
DSDwi Nurcahya Ananda Suwarya
Dwi Nurcahya Ananda Suwarya
IIIrnizarifka Irnizarifka
Irnizarifka Irnizarifka
1. Brugada syndrome (BrS) is a rare inherited cardiac sodium channelopathy associated with malignant ventricular arrhythmias and sudden cardiac death (SCD) in structurally normal hearts [1]. Althou...